Published • loading... • Updated
Tonix Pharmaceuticals Publishes Mpox Research Supporting TNX-801 Vaccine Development
Summary by citybuzz.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Tonix Pharmaceuticals Publishes Mpox Research Supporting TNX-801 Vaccine Development
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the publication of new preclinical research in the peer-reviewed Journal of Virology that demonstrates significant differences in virulence between mpox virus clade IIb, the strain currently circulating in the United States, and the historic clade IIa strain. The study, conducted at the company’s research and development center, identified three new mouse models for investigating mpox …
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
